The Pharma Letter1d
Russia’s Axelpharm continues disputes with Pfizer over generic axitinib
The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...
The American Journal of Managed Care1mon
Real-World Data Support First-Line Avelumab Plus Axitinib in Advanced RCC
Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University ...